144 related articles for article (PubMed ID: 16829852)
1. Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Roesch A; Wittschier S; Becker B; Landthaler M; Vogt T
Mod Pathol; 2006 Oct; 19(10):1378-85. PubMed ID: 16829852
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD26/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin.
Van den Oord JJ
Br J Dermatol; 1998 Apr; 138(4):615-21. PubMed ID: 9640365
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
6. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Jørgensen K; Davidson B; Flørenes VA
Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
[TBL] [Abstract][Full Text] [Related]
7. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions.
Li LX; Crotty KA; McCarthy SW; Palmer AA; Kril JJ
Am J Dermatopathol; 2000 Dec; 22(6):489-95. PubMed ID: 11190439
[TBL] [Abstract][Full Text] [Related]
8. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
9. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
[TBL] [Abstract][Full Text] [Related]
10. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
11. Malignant melanoma with paradoxical maturation.
Ruhoy SM; Prieto VG; Eliason SL; Grichnik JM; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Dec; 24(12):1600-14. PubMed ID: 11117780
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
13. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.
Roesch A; Becker B; Meyer S; Wild P; Hafner C; Landthaler M; Vogt T
Mod Pathol; 2005 Sep; 18(9):1249-57. PubMed ID: 15803180
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
15. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
16. C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.
Lin YC; Chang YM; Ho JY; Lin HC; Tsai YM; Chiang CP; Wang WM; Gao HW
Am J Dermatopathol; 2013 Jul; 35(5):569-75. PubMed ID: 23221472
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
18. Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis.
Massi D; De Nisi MC; Franchi A; Mourmouras V; Baroni G; Panelos J; Santucci M; Miracco C
Mod Pathol; 2009 Jan; 22(1):21-30. PubMed ID: 18660796
[TBL] [Abstract][Full Text] [Related]
19. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase expression in cutaneous melanocytic neoplasms.
Kapur P; Rakheja D; Roy LC; Hoang MP
Mod Pathol; 2005 Aug; 18(8):1107-12. PubMed ID: 15920554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
